Lovestone Simon, Güntert Andreas, Hye Abdul, Lynham Steven, Thambisetty Madhav, Ward Malcolm
Institute of Psychiatry, MRC Centre for Neurodegeneration Research and NIHR Biomedical Research Centre, KCL, London, UK.
Expert Rev Proteomics. 2007 Apr;4(2):227-38. doi: 10.1586/14789450.4.2.227.
Alzheimer's disease is the scourge of the modern, aging world: a costly, damaging disease that robs the elderly of their ability to function as well as their memories. Three decades of progress have resulted in a deep understanding of the pathological processes and a range of targets for therapy, many of which have advanced to late-stage clinical trials. Proteomics has contributed greatly to these advances and will continue to have a growing role in determining the nature of the pathological lesions in the brain. In addition, proteomics (both gel based and gel free, mass spectrometry based), is likely to play an increasing role in identifying biomarkers that may assist in early diagnosis and in monitoring progression and, most importantly, response to therapy.
一种代价高昂、具有破坏性的疾病，它剥夺了老年人的行动能力和记忆力。三十年来的研究进展使人们对其病理过程有了深入了解，并确定了一系列治疗靶点，其中许多靶点已进入后期临床试验阶段。蛋白质组学为这些进展做出了巨大贡献，并将在确定大脑病理损伤的性质方面继续发挥越来越重要的作用。此外，蛋白质组学（基于凝胶和非凝胶、基于质谱）在识别生物标志物方面可能会发挥越来越重要的作用，这些生物标志物有助于早期诊断、监测病情进展，最重要的是，监测对治疗的反应。
